NCT06091319Recruiting
Florbetaben for Imaging of Vascular Amyloid
Florbetaben for Imaging of Vascular Amyloid: Evaluation of Amyloid Inflammasome Imaging in Carotid and Coronary Arteries in Patients With Unstable Atherosclerosis- A Pilot Study
Source: ClinicalTrials.gov · Last updated 8 Sept 2026
Brief summary (registry, in English)
The Primary Objective is to determine if a new nuclear tracer (named 18F-Florbetaben) used with nuclear imaging (PET imaging) can detect inflamed plaque in patients with recent ACS or stroke/TIA.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 11 Aug 2023
- Start date
- 9 Oct 2023
- Primary completion date
- 1 Dec 2026
- Lead sponsor
- Ottawa Heart Institute Research Corporation
- Diseases
- Coronary artery disease, Stroke
- NCT number
- NCT06091319
What you commit to
- Study type: Observational
- Planned participants: 30
- From 9 Oct 2023 to the primary completion date, 1 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- severe valve disease requiring intervention;
- decompensated heart failure;
- Florbetaben allergy;
Lab values
- glomerular filtration rate (GFR) \<50 ml/min/1.72m2
- Exclusion for CTA portion of the protocol: Patients with dye allergy, or those with GFR \<60, will not undergo CTA but will have PET/CT.
Other
- a recent CV event likely to have been embolic in the opinion of the neurologist or cardiologist;
- severe LV dysfunction (EF\<30%);
- pregnancy (all women of child bearing potential will have a negative BHCG test;
- breastfeeding;
- women of childbearing potential who refuse to use two forms of contraception (this includes at least one form of highly effective and one effective method of contraception) throughout the study OR men capable of fathering a child who refuse to use contraception;.
- unable to give informed consent;.
Who the study is looking for
- suffered a recent cardiovascular event (30-120 days post ACS (i.e. STEMI or NSTEMI) or TIA/stroke with ipsilateral large vessel atherosclerotic disease confirmed on US, CT or MRI;
- stable symptoms and hemodynamics;
- age \>/= 18 years;
- given informed consent.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Ottawa Heart Institute Coordinator of this site? Confirm its status | Ottawa | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.